Aprea Therapeutics (NASDAQ:APRE) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Aprea Therapeutics (NASDAQ:APRE) had its price target lowered by analysts at HC Wainwright from $20.00 to $5.00. They now have a "buy" rating on the stock.
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update [Yahoo! Finance]